General Announcement::Initial public offering of equity shares of our WOS Glenmark Life Sciences Limited

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
03-Aug-2021 22:52:14
Status
New
Announcement Sub Title
Initial public offering of equity shares of our WOS Glenmark Life Sciences Limited
Announcement Reference
SG210803OTHRAFNS
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary and Compliance Officer
Effective Date and Time of the event
03/08/2021 00:00:00
Description (Please provide a detailed description of the event in the box below)
Sub: Initial public offering ( Offer ) of equity shares of our wholly owned subsidiary Glenmark Life Sciences Limited
This is further to our intimations dated April 16, 2021 and July 20, 2021 regarding the submission of the draft red herring prospectus dated April 16, 2021 ( DRHP ), with the Securities and Exchange Board of India and filing of the red herring prospectus dated July 19, 2021 with the Registrar of Companies, Pune at Maharashtra ( ROC ) by our wholly owned subsidiary, Glenmark Life Sciences Limited. We would like to inform you of the following:
a. The IPO comprised of a fresh issue of 14,722,222 equity shares by Glenmark Life Sciences Limited and an offer for sale of 6,300,000 equity shares by the Company. The IPO opened for subscription on July 27, 2021 and closed on July 29, 2021.
b. Glenmark Life Sciences Limited filed the prospectus with the ROC on July 30, 2021.
c. The equity shares of the Glenmark Life Sciences Limited, pursuant to the IPO, were allotted at an offer price of Rs. 720 per equity share, to the successful bidders on August 3, 2021.

Attachments

SGX_ALLOTMENT_03082021.pdf
Total size =55K